Australian Pharmaceutical Industries Limited engages in the wholesale distribution of pharmaceutical, medical, health, beauty, and lifestyle products to pharmacies primarily in Australia. More Details
No risks detected for API from our risk checks.
Undervalued with solid track record.
Share Price & News
How has Australian Pharmaceutical Industries's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: API has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: API underperformed the Australian Healthcare industry which returned 5.7% over the past year.
Return vs Market: API underperformed the Australian Market which returned -12% over the past year.
Price Volatility Vs. Market
How volatile is Australian Pharmaceutical Industries's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall StAustralian Pharmaceutical Industries Limited (ASX:API) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
2 weeks ago | Simply Wall StShould You Use Australian Pharmaceutical Industries's (ASX:API) Statutory Earnings To Analyse It?
1 month ago | Simply Wall StMarket Sees Little To Confide In Australian Pharmaceutical Industries Limited (ASX:API) Yet
Is Australian Pharmaceutical Industries undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: API (A$1.02) is trading below our estimate of fair value (A$1.48)
Significantly Below Fair Value: API is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: API is good value based on its PE Ratio (9.5x) compared to the AU Healthcare industry average (28.8x).
PE vs Market: API is good value based on its PE Ratio (9.5x) compared to the Australian market (19.8x).
Price to Earnings Growth Ratio
PEG Ratio: API is poor value based on its PEG Ratio (1.2x)
Price to Book Ratio
PB vs Industry: API is good value based on its PB Ratio (1x) compared to the AU Healthcare industry average (1.4x).
How is Australian Pharmaceutical Industries forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: API's forecast earnings growth (8% per year) is above the savings rate (2.3%).
Earnings vs Market: API's earnings (8% per year) are forecast to grow slower than the Australian market (19.4% per year).
High Growth Earnings: API's earnings are forecast to grow, but not significantly.
Revenue vs Market: API's revenue is expected to decline over the next 3 years (-0.4% per year).
High Growth Revenue: API's revenue is forecast to decline over the next 3 years (-0.4% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: API's Return on Equity is forecast to be low in 3 years time (8.2%).
How has Australian Pharmaceutical Industries performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: API has high quality earnings.
Growing Profit Margin: API's current net profit margins (1.3%) are higher than last year (1.2%).
Past Earnings Growth Analysis
Earnings Trend: API's earnings have grown by 2.7% per year over the past 5 years.
Accelerating Growth: API's earnings growth over the past year (11%) exceeds its 5-year average (2.7% per year).
Earnings vs Industry: API earnings growth over the past year (11%) exceeded the Healthcare industry -6.1%.
Return on Equity
High ROE: API's Return on Equity (10.6%) is considered low.
How is Australian Pharmaceutical Industries's financial position?
Financial Position Analysis
Short Term Liabilities: API's short term assets (A$1.0B) exceed its short term liabilities (A$809.7M).
Long Term Liabilities: API's short term assets (A$1.0B) exceed its long term liabilities (A$340.2M).
Debt to Equity History and Analysis
Debt Level: API's debt to equity ratio (27.7%) is considered satisfactory.
Reducing Debt: API's debt to equity ratio has increased from 16.9% to 27.7% over the past 5 years.
Debt Coverage: API's debt is well covered by operating cash flow (150.9%).
Interest Coverage: API's interest payments on its debt are well covered by EBIT (9.8x coverage).
What is Australian Pharmaceutical Industries's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate API's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate API's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if API's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if API's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: API is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of API's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Richard C. Vincent, B.Bus, (Accountancy), CPA, has been Chief Executive Officer, Managing Director and Executive Director at Australian Pharmaceutical Industries Limited since February 15, 2017. Mr. Vi ...
CEO Compensation Analysis
Compensation vs Market: Richard's total compensation ($USD932.14K) is about average for companies of similar size in the Australian market ($USD746.15K).
Compensation vs Earnings: Richard's compensation has been consistent with company performance over the past year.
|MD, CEO & Executive Director||3.58yrs||AU$1.27m||0.091% |
|Chief Financial Officer||5.67yrs||AU$554.57k||0.0094% |
|Chief Information Officer||3.75yrs||no data||no data|
|General Counsel & Company Secretary||1.17yrs||no data||no data|
|General Manager of People||no data||AU$435.21k||no data|
|NSW State Manager||no data||AU$251.36k||no data|
Experienced Management: API's management team is considered experienced (3.7 years average tenure).
|MD, CEO & Executive Director||3.58yrs||AU$1.27m||0.091% |
|Interim Independent Non-Executive Chairman||no data||AU$178.07k||0.0061% |
|Independent Non-Executive Director||11.92yrs||AU$110.99k||0.017% |
|Independent Non-Executive Director||2.83yrs||AU$110.99k||0.010% |
Experienced Board: API's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Australian Pharmaceutical Industries Limited's company bio, employee growth, exchange listings and data sources
- Name: Australian Pharmaceutical Industries Limited
- Ticker: API
- Exchange: ASX
- Founded: 1910
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: AU$502.509m
- Shares outstanding: 492.66m
- Website: https://www.api.net.au
- Australian Pharmaceutical Industries Limited
- 250 Camberwell Road
- Level 5
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|API||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Jun 1997|
|API||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Jun 1997|
Australian Pharmaceutical Industries Limited engages in the wholesale distribution of pharmaceutical, medical, health, beauty, and lifestyle products to pharmacies primarily in Australia. The company also ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/18 19:03|
|End of Day Share Price||2020/09/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.